Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Schistosoma Mansoni Infection on MVA85A Vaccine in Adolescents
NCT02178748Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Jun 2014
- Primary completion
- Jan 2015
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of MVA85A in Tuberculosis (TB) (2 arms), sponsored by University of Oxford. Primary endpoint: T cell immunogenicity by gamma-interferon ELISPOT of Ag85A response at 8 weeks. Started Jun 2014; status: completed.
02
Drugs
MVA85A
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02178748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02178748.